[{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ DCVC Bio"},{"orgOrder":0,"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Launches to Transform the Treatment of Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"suPAR","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Walden Biosciences","amount2":0.050000000000000003,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Walden Biosciences \/ ARCH Venture Partners","highestDevelopmentStatusID":"2","companyTruncated":"Walden Biosciences \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harvard University and Kyowa Kirin Enter Strategic Research Alliance","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyowa Kirin \/ Harvard University","highestDevelopmentStatusID":"2","companyTruncated":"Kyowa Kirin \/ Harvard University"},{"orgOrder":0,"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Lilly Enter Into Drug Discovery Collaboration in Metabolic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Evotec","amount2":1,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":1,"dosageForm":"Oral","sponsorNew":"Evotec \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Eli Lilly"},{"orgOrder":0,"company":"Multiomic Health","sponsor":"Hoxton Ventures","pharmaFlowCategory":"D","amount":"$8.6 million","upfrontCash":"Undisclosed","newsHeadline":"MultiOmic Health Closes $6.2 Million Funding Round to Discover Precision Medicines for Metabolic Syndrome-Related Conditions","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Multiomic Health","amount2":0.01,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Multiomic Health \/ Hoxton Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Multiomic Health \/ Hoxton Ventures"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Chinook Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"Ionis Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ionis Pharmaceuticals \/ Chinook Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Ionis Pharmaceuticals \/ Chinook Therapeutics"},{"orgOrder":0,"company":"One Biosciences","sponsor":"AP-HP","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"One Biosciences Partners with AP-HP to Launch a Single-cell Research Project on a Rare Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Nephrology","graph2":"Discovery","graph3":"One Biosciences","amount2":0,"therapeuticAreaNew":"Nephrology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"One Biosciences \/ AP-HP","highestDevelopmentStatusID":"2","companyTruncated":"One Biosciences \/ AP-HP"}]

Find Novel Nephrology Drugs in Discovery

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Under the partnership, One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : AP-HP

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The companies will leverage Chinook’s precision medicine approach and expertise in nephrology and Ionis’ expertise in RNA-targeted therapeutics for discovery, development and commercialization of an antisense oligonucleotide therapy for a rare, sever...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 16, 2023

                          Lead Product(s) : Antisense Oligonucleotide-based Therapy

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : Chinook Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The net proceeds of the financing round will be used to to discover precision medicines for metabolic syndrome-related conditions and to demonstrate proof-of-concept for MultiOmic’s MOHSAIC® platform in diabetic kidney disease.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 03, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : Hoxton Ventures

                          Deal Size : $8.6 million

                          Deal Type : Financing

                          blank

                          04

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Under the agreement, Evotec will be responsible for the discovery of drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or Evotec. Lilly reserves the right to select upto five programmes developed w...

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 18, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : Eli Lilly

                          Deal Size : $1,000.0 million

                          Deal Type : Collaboration

                          blank

                          05

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 26, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : Harvard University

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 06, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : ARCH Venture Partners

                          Deal Size : $51.0 million

                          Deal Type : Series A Financing

                          blank

                          07

                          Fall Technical Meeting
                          Not Confirmed
                          Fall Technical Meeting
                          Not Confirmed

                          Details : The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 07, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : DCVC Bio

                          Deal Size : $33.0 million

                          Deal Type : Series A Financing